Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Breast Cancer
Erschienen in: Breast Cancer 3/2013

01.07.2013 | Case Report

Ductal carcinoma in situ with isolated tumor cells in the sentinel lymph node in a 17-year-old adolescent girl

verfasst von: Tomoi Sato, Ichiro Muto, Masaki Hasegawa, Takashi Aono, Takeshi Sakai, Takeshi Oya

Erschienen in: Breast Cancer | Ausgabe 3/2013

Einloggen, um Zugang zu erhalten

Abstract

We report here a quite rare case of ductal carcinoma in situ (DCIS) with isolated tumor cells in the sentinel lymph node in a 17-year-old adolescent girl whose mother also had advanced breast cancer. Findings included an elastic mass in the right breast accompanied by serous nipple discharge. DCIS of the breast was diagnosed following core needle biopsy. Although no invasive focus was clearly observed in the mastectomy sample, isolated tumor cells were found in the sentinel lymph node. Although the family refused genetic testing, a hereditary abnormality may have played a role in the carcinogenesis in this case.
Literatur
1.
2.
The Japanese Breast Cancer Society. General rules for clinical and pathological recording of breast cancer 2005. Breast Cancer 2005;Suppl 12.
3.
Rosen PP. Intraductal carcinoma. In: Rosen PP, editor. Rosen’s breast pathology. Philadelphia: Lippincott-Raven; 1996. p. 227–73.
4.
Sobin LH, Wittekind CH, editors. TNM classification of malignant tumors. 6th ed. New York: Wiley; 2002. p. 9–13.
5.
Horner MJ, Ries LAG, Krapcho M, Neyman N, Aminou R, Howlader N, Altekruse SF, Feuer EJ, Huang L, Mariotto A, Miller BA, Lewis DR, Eisner MP, Stinchcomb DG, Edwards BD, editors. SEER cancer statistics review, 1975–2006. Bethesda: National Cancer Institute; 2009. http://​seer.​cancer.​gov/​csr/​1975_​2006/​, based on November 2008 SEER data submission. Accessed 24 Nov 2009.
6.
Rogers DA, Lobe TE, Rao BN, Fleming ID, Schropp KP. Breast malignancy in children. J Pediatr Surg. 1994;29:48–51.CrossRefPubMed
7.
Murphy JJ, Morzaria S, Gow KW, Magee JF. Breast cancer in a 6-year-old child. J Pediatr Surg. 2000;35:765–7.CrossRefPubMed
8.
Corroppolo M, Erculiani E, Zampieri N, Gobbato M, Camoglio FS, Giacomello L. Ductal carcinoma in situ in a 15-year-old boy with gynecomastia: a case report. Pediatr Surg Int. 2008;24:943–5.CrossRefPubMed
9.
Tea MK, Asseryanis E, Kroiss R, Kubista E, Wagner T. Surgical breast lesions in adolescent females. Pediatr Surg Int. 2009;25:73–5.CrossRefPubMed
10.
Arai M, Utsunomiya J, Miki Y. Familial breast and ovarian cancers. Int J Clin Oncol. 2004;9:270–82.CrossRefPubMed
11.
Youngson BJ, Cranor M, Rosen PP. Epithelial displacement in surgical breast specimens following needling procedures. Am J Surg Pathol. 1994;18:898–903.CrossRef
12.
Bleiweiss IJ, Nagi CS, Jaffer S. Axillary sentinel lymph nodes can be falsely positive due to iatrogenic displacement and transport of benign epithelial cells in patients with breast carcinoma. J Clin Oncol. 2006;24:2013–8.CrossRefPubMed
13.
van Rijk MC, Peterse JL, Nieweg OE, Oldenburg HA, Rutgers EJ, Kroon BB. Additional axillary metastases and stage migration in breast cancer patients with micrometastases or submictometastases in sentinel lymph nodes. Cancer. 2006;107:467–71.CrossRefPubMed
14.
Reed J, Rosman M, Verbanac KM, Mannie A, Cheng Z, Tafra L. Prognostic implications of isolated tumor cells and micrometastases in sentinel nodes of patients with invasive breast cancer: 10-year analysis of patients enrolled in the Prospective East Carolina University/Anne Arundel Medical Center Sentinel Node Multicenter Study. J Am Coll Surg. 2009;208:333–40.CrossRefPubMed
15.
McCready DR, Yong WS, Ng AKT, Miller N, Done S, Youngson B. Influence of the new AJCC breast cancer staging system on sentinel lymph node positivity and false-negative rates. J Natl Cancer Inst. 2004;96:873–5.CrossRefPubMed
16.
Turner RR, Chu KU, Qi K, Botnick LE, Hansen NM, Glass EC, Giuliano AE. Pathologic features associated with nonsentinel lymph node metastases in patients with metastatic breast carcinoma in a sentinel lymph node. Cancer. 2000;89:574–81.CrossRefPubMed
17.
Kamath VJ, Giuliano R, Dauway EL, Cantor A, Berman C, Ku NN, et al. Characteristics of the sentinel lymph node in breast cancer predict further involvement of higher-echelon nodes in the axilla: a study to evaluate the need for complete axillary lymph node dissection. Arch Surg. 2001;136:688–92.CrossRefPubMed
18.
19.
Serour F, Gilad A, Kopolovic J, Krispin M. Secretory breast cancer in childhood and adolescence: report of a case and review of the literature. Med Padiatr Oncol. 1992;20:341–4.CrossRef
20.
Herz H, Cooke B, Goldstein D. Metastatic secretory breast cancer. Non-responsiveness to chemotherapy: case report and review of the literature. Ann Oncol. 2000;11:1343–7.CrossRefPubMed
21.
Walker RA, Lees E, Webb MB, Dearing SJ. Breast carcinomas occurring in young women (<35 years) are different. Br J Cancer. 1996;74:1796–800.CrossRefPubMed
22.
Maggard MA, O’Connell JB, Lane KE, Liu JH, Etzioni DA, Ko CY. Do young breast cancer patients have worse outcome? J Surg Res. 2003;113:109–13.CrossRefPubMed
23.
National Institutes of Health Consensus Development Panel. National Institutes of Health Consensus Development Conference statement: adjuvant therapy for breast cancer, November 1–3, 2000. J Natl Cancer Inst Monogr. 2001;30:5–15.CrossRef
24.
Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B, Senn HJ, et al. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol. 2007;18:1133–44.CrossRefPubMed
25.
Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thurlimann B, Senn HJ, et al. Thresholds for therapies: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2009. Ann Oncol. 2009;20:1319–29.CrossRefPubMed
Metadaten
Titel
Ductal carcinoma in situ with isolated tumor cells in the sentinel lymph node in a 17-year-old adolescent girl
verfasst von
Tomoi Sato
Ichiro Muto
Masaki Hasegawa
Takashi Aono
Takeshi Sakai
Takeshi Oya
Publikationsdatum
01.07.2013
Verlag
Springer Japan
Erschienen in
Breast Cancer / Ausgabe 3/2013
Print ISSN: 1340-6868
Elektronische ISSN: 1880-4233
DOI
https://doi.org/10.1007/s12282-010-0205-x

Weitere Artikel der Ausgabe 3/2013

Breast Cancer 3/2013 Zur Ausgabe

Review Article

Animal model for mammary tumor growth in the bone microenvironment

Letter to the Editor

Measuring of the maximum fat lesion ratio

Original Article

Physicians’ knowledge, attitude, and behavior regarding fertility issues for young breast cancer patients: a national survey for breast care specialists

Original Article

Impact of aggregate of risk factors for isolated locoregional failure in breast cancer patients treated with mastectomy without radiotherapy

Original Article

Sentinel lymph node biopsy in patients with breast cancer using superparamagnetic iron oxide and a magnetometer

Original Article

Identification of candidates for postmastectomy radiotherapy in patients with pT3N0M0 breast cancer

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

23.04.2024 Medikamente in Schwangerschaft und Stillzeit Nachrichten

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise